Building on this idea, ongoing phase I/II studies of the GLS inhibitor CB-839 in combination with osimertinib is being tested for EGFR-mutant NSCLC (NCT03831932) and CB-839 with palbociclib for solid tumours (NCT03965845) (Table 2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.